Develops gene-edited cell therapies for sickle cell disease and beta thalassemia.
Jun 2026Revenue $13.4M/yrExpenses $548M/yr
No trendCash runway ≈ 6.4 years from Jun 2026
Figures by year
When will CRISPR Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $13.4M and expenses $548M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $3.51M | $668M | −$665M |
| Dec 2024 | $37.3M | $504M | −$467M |
| Dec 2023 | $371M | $594M | −$223M |
| Dec 2022 | $1.20M | $674M | −$673M |
| Dec 2021 | $915M | $541M | $374M |
| Dec 2020 | $719K | $355M | −$354M |
| Dec 2019 | $290M | $243M | $46.7M |
| Dec 2018 | $3.12M | $162M | −$159M |
| Dec 2017 | $41.0M | $106M | −$64.6M |
| Dec 2016 | $5.16M | $73.3M | −$68.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.